Cancer Chemotherapy and Biotherapy: Principles and Practice

Updated to include the newest drugs and those currently in development, Cancer Chemotherapy and Biotherapy, Fifth Edition is a comprehensive reference on the preclinical and clinical pharmacology of anticancer agents. Organized by drug class, the book provides the latest information on all drugs and biological agents—their mechanisms of action, interactions with other agents, toxicities, side effects, and mechanisms of resistance. Chapters emphasize pharmacology and mechanisms of action at the molecular and cellular levels, followed by clinical activity and toxicity, both acute and delayed. The authors explain the rationale for use of drugs in specific schedules and combinations and offer guidelines for dose adjustment in particular situations.

This edition's introduction includes timely information on general strategies for drug usage, the science of drug discovery and development, economic and regulatory aspects of cancer drug development, and principles of pharmacokinetics. Eight new chapters have been added and more than twenty have been significantly revised.

A companion website includes the fully searchable text and an image bank.

--NEW! Introductory section completely overhauled to include new information on:
-- general strategies for drug usage
-- the science of drug discovery and development
-- economic and regulatory aspects of cancer drug development
-- principles of pharmacokinetics
--NEW! Eight new chapters added, seven revised with new authors
--NEW! Significant overhaul to more than 20 other chapters, especially drug information
--Organized by drug class, not disease
--Illustrates mechanism of action and structure of each drug, as well as its toxicity
--Complete discussion of drug interactions
--Covers all new drugs as well as those in development

Editor Bruce A Chabner MD

Professor of Medicine, Chief, Hematology/Oncology, Clinical Director, Cancer Center, Massachusetts General Hospital, Boston, MA
Editor Dan L Longo MD

National Institute on Aging, National Institutes of Health, Gerontology Research Center, Baltimore, MD

Table Of Contents
Section 1: BASIC PRINCIPLES OF CANCER TREATMENT

1: Clinical Strategies for Cancer Treatment: The Role of Drugs
Bruce Chabner

2: Target Identification and Drug Discovery
Ed Sausville

3: Clinical Drug Development and Approval for Marketing
Thomas Roberts

4: Principles of Pharmacokinetics
Jerry Collins

5: Special Aspects of Brain Tumor Chemotherapy
Jeffrey Supko & Tracy Batchelor

6: Pharmacogenetics
Howard McLeod

7: Barriers to Drug Delivery
Brendan Curti

Section 2: CYTOTOXIC AGENTS

8: Antifolates
Carmen Allegra & Bruce Chabner

9: Fluoro-pyrimidines
David Ryan, Bruce Chabner & Ray Wadlow

10: Cytidine Analogues
David Ryan & Bruce Chabner

11: Purine Analogues
Ken Hande

12: Hydroxyurea
Bruce Chabner

13: Antimitotic Drugs
Ross Donehower

14: Alkylating Agents (Including Methylating Agents)
Stan Gerson & Henry Friedman

15: Platinum Analogues
Ed Reed

16: Antitumor Antibiotics (Including Bleomycin)
Bruce Chabner

17: Topoisomerase I Inhibitors
Alex Spaareboom & William Zamboni

18: Topoisomerase II Inhibitors: Anthracyclines
Jim Doroshow

19: Topoisomerase II Inhibitors: Etoposide, Teniposide
George Hartman & Yves Pommier

20: L-Asparaginase
Bruce Chabner & Alison Friedmann

Section 3: MOLECULARLY TARGETED THERAPIES

21: Proteosome Inhibitors
Orhan Sezar

22: HDAC Inhibitors
Susan Bates

23: Differentiating Agents (Retinoids)
Bruce Chabner

24: Arsenic Trioxide
Bruce Chabner

25: Monoclonal Antibodies: Discovery & Development
David Scheinberg

26: Anti-angiogenic Agents (Including MonAB)
William Gradishar & Kari Wisinski

27: Anti-EGFR Therapies (Including MonAB)
Lecia Sequist & Joel Neal

28: Anti-her 2 Therapies
Eric Winer

29: Intracellular Signal Inhibitors (bcr-abl)
Bruce Chabner & Jeffrey Barnes

30: Signal Transduction Inhibitors in Development
Jeff Clark

31: Inhibitors of the PI3k Pathway & Mitotic Kinase
Percy Ivy

Section 4: IMMUNOLOGIC AGENTS

32: Interferon and Cytokines
David McDermott

33: Vaccines
Robert G. Fenton

34: Adoptive Cellular Therapies
Cassian Yee

35: Immuno-modulatory Drugs (IMIDS, Anti-CTLA4)
Paul Richardson et al.

Section 5: HORMONAL THERAPY

36: Hormonal Therapy of Breast Cancer
Beverly Moy & Paul Goss

37: GNRH Agonists and Anti-Androgens
Richard Lee

Section 6: SUPPORTIVE CARE

38: Pain Management in Cancer Patients
Paul Glare

39: Colony Stimulating Factors
Gary Lyman

40: Anti-nausea Medications
Ian Olver

41: Bone Loss Modulators
Matthew Smith

42: Intravenous Access and Catheter Management
Rachel Rosovsky

Section 7: SURVIVORSHIP

43: Monitoring for Late Side Effects of Chemotherapy
Richard Schilsky, Charles Erlichman & Brian Costello


Actualizate pentru a include cele mai noi medicamente şi cele in curs de dezvoltare, Cancer Chimioterapia şi Bioterapia, a cincea Edition este o referinţă cuprinzătoare privind farmacologice preclinice şi clinice ale agenţilor împotriva cancerului. Organizat de clasa de droguri, cartea oferă cele mai recente informaţii cu privire la toate drogurile şi agenţi biologici-lor mecanisme de acţiune, interacţiuni cu alţi agenţi, toxicitate, efecte secundare, şi mecanismele de rezistenţă. Capitolele sublinia farmacologice şi a mecanismelor de acţiune la nivel celular si molecular, urmată de activitatea clinică şi toxicitatea, atât acută cât şi întârziate. Autorii explica raţiunea pentru utilizarea de droguri în programele specifice şi combinaţii de linii directoare şi oferta pentru ajustarea dozei în situaţii particulare.

Introducerea Această ediţie include informaţii în timp util cu privire la strategiile generale de utilizare de droguri, ştiinţa de descoperirea de droguri şi de dezvoltare, aspecte economice şi de reglementare de dezvoltare a cancerului de droguri, şi principiile de farmacocinetica. Opt capitole au fost adăugate noi şi mai mult de douăzeci au fost revizuite în mod semnificativ.

Un website de companie include textul complet căutat şi o bancă imagine.

- NOU! secţiunea introductivă complet revizuit pentru a include noi informaţii cu privire la:
- Strategiile generale pentru utilizarea de droguri
- Ştiinţa de descoperirea de droguri şi de dezvoltare
- Aspectele economice şi de reglementare de dezvoltare a cancerului de droguri
- Principiile de farmacocinetica
- NOU! Opt capitole noi adăugate, şapte revizuite cu noi autori
- NOU! revizia semnificative la mai mult de alte 20 de capitole, în special informaţiile despre droguri
- Organizat de clasa de droguri nu, boala
- Mecanism Ilustrează de acţiune şi a structurii fiecărei droguri, precum şi toxicitatea sa
- Discuţie completă de interacţiuni medicamentoase
- Acoperă toate de noi medicamente, precum şi cele în dezvoltare

Editor Bruce Un Chabner MD

Profesor de Medicină, şef, Hematologie / Oncologie, Director clinică, Centrul de Cancer, Massachusetts General Hospital, Boston, MA
Editor L Longo Dan MD

National Institute on Aging, Institutul National de Sanatate, Centrul de Cercetare Gerontologie, Baltimore, MD

Cuprins
Secţiunea 1: PRINCIPII DE BAZĂ DE tratamentul cancerului

Strategii clinice pentru tratamentul cancerului:: 1 Rolul de droguri
Bruce Chabner

2: Discovery ţintă de identificare şi de droguri
Ed Sausville

3: Dezvoltarea de droguri clinice şi de aprobare pentru marketing
Thomas Roberts

4: Principii de Farmacocinetica
Jerry Collins

5: Aspecte speciale ale chimioterapiei tumoare pe creier
Jeffrey Supko & Batchelor Tracy

6: farmacogenetică
Howard McLeod

7: Bariere de livrare de droguri
Brendan Curti

Secţiunea 2: citotoxice

8: Antifolates
Carmen Allegra & Chabner Bruce

9: fluoro-pirimidinelor
David Ryan, Chabner Bruce & Wadlow Ray

10: analogi de citidină
David Ryan & Chabner Bruce

11: Analogii purinici
Ken Hande

12: Hidroxiureea
Bruce Chabner

13: Droguri antimitotic
Ross Donehower

14: agenti alchilanti (inclusiv agenţii Methylating)
Stan Gerson & Friedman Henry

15: Analogii Platinum
Ed Reed

16: Antibiotice antitumorale (Inclusiv Bleomycin)
Bruce Chabner

17: Inhibitori topoizomeraza I
Alex & Spaareboom Zamboni William

18: Inhibitori topoizomeraza II: antracicline
Jim Doroshow

19: Inhibitori topoizomeraza II: Etoposide, Teniposide
George Hartman & Pommier Yves

20: L-asparaginaza
Bruce Chabner & Alison Friedmann

Secţiunea 3: TERAPII molecular ŢINTĂ

21: Inhibitori Proteosome
Orhan Sezar

22: Inhibitori HDAC
Susan Bates

Agenţi Diferenţierea (Retinoizi): 23
Bruce Chabner

24: trioxid de arsen
Bruce Chabner

25: anticorpi monoclonali: Discovery & Dezvoltare
David Scheinberg

26: agenţi anti-angiogenice (Inclusiv MonAB)
William Gradishar & Kari Wisinski

27: terapii anti-EGFR (Inclusiv MonAB)
Lecia Sequist & Neal Joel

28: Anti-ei 2 terapii
Eric Winer

29: Inhibitori intracelulară de semnal (BCR-ABL)
Bruce Chabner Barnes & Jeffrey

30: Inhibitori transducţie a semnalelor în dezvoltare
Jeff Clark

31: Inhibitori de Pathway PI3-K & mitotic KinazÄ
Percy Ivy

Secţiunea 4: AGENŢI imunologic

32: Interferon şi citokine
David McDermott

33: Vaccinurile
Robert G. Fenton

34: de adopţie terapii celulare
Cassian Yee

35: Droguri imuno-modulatoare (IMiDs, Anti-CTLA4)
Paul Richardson et al.

Secţiunea 5: terapie hormonală

Terapiei hormonale de cancer de san: 36
Beverly Moy & Goss Paul

37: agoniştii GnRH şi anti-Androgenii
Richard Lee

Secţiunea 6: terapia de susţinere

38: Managementul Durerii la pacienţii cu cancer
Paul Glare

39: Colony factori de stimulare a
Gary Lyman

Medicamente anti-greaţă: 40
Ian Olver

Modulatoare Bone Pierdere: 41
Matthew Smith

42: Accesul intravenos şi cateter Management
Rachel Rosovsky

Secţiunea 7: urmas

43: de monitorizare a efectelor secundare ale chimioterapiei Late
Richard Schilsky, Charles Erlichman & Costello Brian